The initial success of Sildenafil undeniably reshaped the pharmaceutical landscape, but investing in companies strongly reliant on unbranded versions presents a uncertain picture. While early earnings were impressive, the end of patents and the emergence of cheaper alternatives have diminished the customer base. Consequently, a thorough analysis of